Last reviewed · How we verify
Standard therapy for INCS
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles. Used for Type 2 diabetes, Polycystic ovary syndrome (PCOS).
At a glance
| Generic name | Standard therapy for INCS |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | biguanide |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Metformin acts by inhibiting the mitochondrial respiratory chain complex I, which decreases hepatic glucose production. It also increases insulin sensitivity by enhancing glucose uptake in muscles and adipose tissue. Additionally, metformin decreases glucose absorption from the gut.
Approved indications
- Type 2 diabetes
- Polycystic ovary syndrome (PCOS)
Common side effects
- Gastrointestinal upset
- Lactic acidosis
Key clinical trials
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
- Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis (NA)
- Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial (NA)
- Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis (EARLY_PHASE1)
- Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT) (PHASE3)
- Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard therapy for INCS CI brief — competitive landscape report
- Standard therapy for INCS updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI